Jennifer Doudna co-founded Peninsula biotech lands CRISPR gene-editing pact with Regeneron

The deal, which could pay the Peninsula company a $100 million upfront and up to $370 million per target, is the third aimed at assembling CRISPR’s components in the body.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks